Paul Chazot

Dr. Paul Chazot is an Associate Professor of Pharmacology in the Department of Biosciences (Durham University, DU) and a Fellow of the British Pharmacological Society (H-index=45). His research group focuses on the identification, characterization, and validation of novel drug and non-drug-based targets and strategies for the treatment of the major chronic CNS pathologies.

Dr. Chazot has developed new clinical development programs: chronic pain (Votucalis), which is in the pipeline stage for the company Akari Therapeutics UK; and Alzheimer's & Parkinson's Disease (PBM-T 1068nm), which are reaching the Phase 2 clinical stage in the US, and now in the UK.

He is also the lead for a novel, award-winning Biopsychosocial Clinical Training program in Primary care for chronic pain self-management.

Finally, Dr. Chazot is the Durham Biology lead for the DU spin-out company Nevrargenics, which has developed exciting new rational drug leads (RAR-M) for disease-modification in a range of neurodegenerative diseases, including CTE.